<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Clinical Neuroscience</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/418AD2D5-33F6-47B7-B374-BA224E2C4309"><gtr:id>418AD2D5-33F6-47B7-B374-BA224E2C4309</gtr:id><gtr:firstName>Elizabeth</gtr:firstName><gtr:otherNames>Jane</gtr:otherNames><gtr:surname>Bradbury</gtr:surname><gtr:orcidId>0000-0003-4252-0234</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G120%2F818"><gtr:id>781F7AD2-5ACE-4F05-B0B2-AB313575BE8C</gtr:id><gtr:title>Promoting plasticity and repair after spinal cord injury</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G120/818</gtr:grantReference><gtr:abstractText>Following a spinal cord injury, damaged nerves do not normally regenerate, meaning communication with other nerve cells is lost. The resulting paralysis and loss of sensation has devastating effects on the lives of patients. Recent advances have increased our understanding of why nerve regeneration fails after spinal cord injury. One of these is the identification of inhibitory factors called proteoglycans. A treatment which degrades proteoglycans can lead to the recovery of walking behaviours in spinal injured rats. It is now vital to understand the mechanisms that underlie these functional improvements in order to optimise this approach. Therefore I aim to investigate the responses of injured and intact spinal systems to proteoglycan degradation and harness beneficial regeneration and compensatory sprouting responses. The second aim will be to test these optimized approaches in an injury model that closely resembles the trauma characteristic of human spinal cord injuries. Such a model (not yet established in the UK) will provide a valuable tool for assessing the therapeutic potential of these treatment strategies. The final aim is to assess whether proteoglycan-degrading treatment strategies can be combined with other interventions to enhance the beneficial effects on functional recovery. The findings generated from this research may have important therapeutic implications for treating spinal cord injury</gtr:abstractText><gtr:technicalSummary>In recent years spinal cord injury research has progressed at a rapid pace, with great advances being made in understanding why this severely debilitating condition is so unresponsive to repair. Chondroitin sulphate proteoglycans (CSPGs) have been identified as important inhibitory molecules associated with the glial scar that forms at CNS injury sites. Recently, I have shown that degrading CSPGs, using the enzyme chondroitinase ABC, can result in the re-establishment of synaptic connections and a recovery of lost sensorimotor function in adult spinal injured rats. Degrading CSPGs has also recently been demonstrated to induce plasticity in the visual system, to an extent normally only seen during development. I hypothesize that CSPGs function in the adult CNS to inhibit intact systems from sprouting as well as damaged systems from regenerating. Thus, the first aim of this proposal is to elucidate mechanisms of CSPG-mediated inhibition, particularly to determine whether exploiting sprouting and plasticity responses may be a key to regaining lost function after spinal cord injury. This will involve investigating the nature of proteoglycan degradation; determining the propensity for different spinal systems to undergo plastic changes; and optimising methods of targeting of CSPGs. I then aim to test the most optimal approaches in a spinal cord injury model that closely resembles the trauma characteristic of human spinal cord injuries. Thus, the second key aim of this proposal is to establish a controlled contusion injury device in the UK. This will involve a period of training at The Ohio State University in order to learn the relevant operational skills, surgical techniques and behavioural outcome measures. This will provide a valuable tool with which to assess the therapeutic potential of interventions aimed at targeting CSPG-mediated inhibition, as well as making available in the UK a clinically relevant spinal cord injury model. The third aim of the proposal is to test the hypothesis that combining CSPG-degrading treatments with neurotrophic factor delivery, and other treatment strategies, will have synergistic effects in enhancing functional recovery following spinal cord injury. I intend to use multiple outcome measures to assess the functional effects of novel treatment strategies, aimed at optimising regeneration and compensatory sprouting responses. Thus, with a Career Development Award I hope to further the goal of determining how the highly rigid spinal cord injury environment can be stimulated to induce and maintain a repair response.</gtr:technicalSummary><gtr:fund><gtr:end>2012-01-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2003-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>619471</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>GSK peripheral nerve regeneration study</gtr:description><gtr:id>3AF7A7DA-DFAA-442A-809F-427BA6B6E9E0</gtr:id><gtr:impact>Research funding for the lab which allowed us to breed and maintain a colony of transgenic mice which have been useful for the study of degeneration and repair following spinal cord injury.</gtr:impact><gtr:outcomeId>A70B16479E9-1</gtr:outcomeId><gtr:piContribution>Conducted an in vivo study to assess the potential of a promising compound for enhancing regneration and functional repair following peripheral nerve injury.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Developmental Neurobiology</gtr:department><gtr:description>PI 3-kinase study/Eickholt collaboration</gtr:description><gtr:id>BF0D2E9A-C2CC-461B-AE85-948FB485C37F</gtr:id><gtr:impact>A publication arose from the collaboration (PubMedID: 17846664)</gtr:impact><gtr:outcomeId>22FD0E685F5-1</gtr:outcomeId><gtr:partnerContribution>Our collaborators have provided valuable research tools such as antibodies and protocols. Also, their expertise in evelopmental neurobiology has identified signalling pathways that are important in growth and survival during development and that may also be important in the adult injured nervous sytem. So this collaboration has led us to new avenues of study.</gtr:partnerContribution><gtr:piContribution>We provided anatomical and functional in vivo data for this study which greatly strengthened the evidence that the p110delta isoform of PI 3-kinase is an important signalling component for succesful regeneration in the injured nervous system.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Newspaper interview</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2A9DDCE7-2E1C-453F-A37F-75F5502CB87F</gtr:id><gtr:impact>After receiving the Schellenberg Prize for Research 2008 I was interviewed by a journalist from a Swiss Newspaper (Tribune de Geneva), where I was asked to describe my research findings and the impact they would have on patient treatment to a lay audience. This is the biggest Swiss newspaper so the interview would have reached a wide audience.

An increased number of enquiries from spinal injured patients/carers/relatives requesting more information about chondroitinase therapy and enquiring about clinical trials in this area.</gtr:impact><gtr:outcomeId>854F6EA6135</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Radio interview</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0F748ED7-047C-4B94-AD57-6E7D1A095707</gtr:id><gtr:impact>After receiving the Schellenberg Prize for Research 2008 I was interviewed by a Swiss Radio station and asked to describe my research findings and the impact they would have on patient treatment to a lay audience. This was the main Swiss Radio staion so would have reached a wide audience.

An increased number of enquiries from spinal injured patients/carers/relatives requesting more information about chondroitinase therapy and enquiring about clinical trials in this area.</gtr:impact><gtr:outcomeId>A589C70BF14</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>251862</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Spinal Research Strategic Research Grant</gtr:description><gtr:end>2011-11-02</gtr:end><gtr:fundingOrg>International Spinal Research Trust (Spinal Research)</gtr:fundingOrg><gtr:fundingRef>STR101</gtr:fundingRef><gtr:id>4E4DCB26-26B8-4557-BF85-8FD6B16C743A</gtr:id><gtr:outcomeId>B8AEBB3BE330</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>25000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>CDRF Award</gtr:description><gtr:fundingOrg>Christopher and Dana Reeve Foundation</gtr:fundingOrg><gtr:id>6651282C-E1E3-4629-B96B-928D72A83CF6</gtr:id><gtr:outcomeId>546350c2386c85.38333738</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60325</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Darwin Trust of Edinburgh</gtr:department><gtr:description>PhD Studentship</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>British Society for the History of Science (BSHS)</gtr:fundingOrg><gtr:id>68A3D5DF-C58B-4A34-A767-1D1239951001</gtr:id><gtr:outcomeId>7DD98A5E7310</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>88002</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Spinal Research Natalie Rose Barr Studentship</gtr:description><gtr:end>2010-09-02</gtr:end><gtr:fundingOrg>International Spinal Research Trust (Spinal Research)</gtr:fundingOrg><gtr:id>2A188A28-0B96-4D28-B6CE-0468E6188894</gtr:id><gtr:outcomeId>E65D307DC650</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>55680</gtr:amountPounds><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Schellenberg Prize for Research 2008/The International Foundations for Research in Paraplegia, IRP Geneva and Zurich</gtr:description><gtr:fundingOrg>International Foundation for Research in Paraplegia (IRP)</gtr:fundingOrg><gtr:id>323B84D7-7E7F-4B07-BE93-BE787589C584</gtr:id><gtr:outcomeId>ri8XbEsZcXs0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1913780</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC SNCF</gtr:description><gtr:end>2016-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G1002055</gtr:fundingRef><gtr:id>029A0D22-A760-4062-996A-91F60C3BAE08</gtr:id><gtr:outcomeId>K3RKPh7bPLd0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-08-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Use of an enzyme treatment to promote plasticity and repair following CNS damage</gtr:description><gtr:grantRef>G120/818</gtr:grantRef><gtr:id>BA6DC32D-386B-4EF0-A2B4-7142CAA08B5D</gtr:id><gtr:impact>The product was licensed by a US-based drug company that specialises in spinal cord injury and multiple sclerosis</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>bpDVfYtjMHe</gtr:outcomeId><gtr:patentId>0205022.7</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Materials and methods for the treatment of CNS damage</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We developed a mouse model of unilateral corticospinal tract injury at the level of the brainstem pyramids, with histological and functional characterisation.</gtr:description><gtr:id>1CD3BE21-A19F-4AEB-8D6E-0332A4F20940</gtr:id><gtr:impact>A novel model for assessing plasticity following unilateral injury in the mouse. Has since been used by a number of labs to show plasticity of an intact spinal pathway following treatment interventiuon and the iumportance of compensatory collateral sprouting in promoting functional recovery following spinal injury.</gtr:impact><gtr:outcomeId>8C151708E9A</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Mouse pyramidotomy model</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Utilised the YFP-H transgenic mouse which has constitutive expression of yellow fluorescent protein in layer V pyramidal neurons, for a novel in vivo methodology to assess degeneration in corticospinal projection neurons following spinal cord injury and neuroprotection following treatment intervention.</gtr:description><gtr:id>19161C07-FA74-4714-9A61-55A25D9B681A</gtr:id><gtr:impact>This novel in vivo methodology for assessing degeneration in spinal projection neurons has led to several collaborations and has also led to the novel finding that degrading extracellular matrix molecules at a spinal injury site can prevent degeneration of descending spinal projection neurons.</gtr:impact><gtr:outcomeId>24360FC3C0C</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>YFP-H mouse model of neuroprotection</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>C4AC4B3B-EEC1-4040-A95C-AC6A04F36FD3</gtr:id><gtr:title>The yellow fluorescent protein (YFP-H) mouse reveals neuroprotection as a novel mechanism underlying chondroitinase ABC-mediated repair after spinal cord injury.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0684ff0a808a8056441bb17890a5be0d"><gtr:id>0684ff0a808a8056441bb17890a5be0d</gtr:id><gtr:otherNames>Carter LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>FA16202DF1C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF02D777-AA65-4083-AB6E-DBBBBBD76BB9</gtr:id><gtr:title>Role of spinal microglia in rat models of peripheral nerve injury and inflammation.</gtr:title><gtr:parentPublicationTitle>European journal of pain (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1fd850989ded61287c6584afcec3265"><gtr:id>b1fd850989ded61287c6584afcec3265</gtr:id><gtr:otherNames>Clark AK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1090-3801</gtr:issn><gtr:outcomeId>DF3639374DD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>25EE63AA-A74E-404D-9A25-24A6AE7266EB</gtr:id><gtr:title>Neural progenitors promote axon growth in vitro and ex vivo but not following injury.</gtr:title><gtr:parentPublicationTitle>Journal of stem cells</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db28e2805c5490d0162abb23ac230c89"><gtr:id>db28e2805c5490d0162abb23ac230c89</gtr:id><gtr:otherNames>Webber DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1556-8539</gtr:issn><gtr:outcomeId>SrP7myBHNEE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>85922673-B720-4A33-97B2-10251A7CED3C</gtr:id><gtr:title>Effects of Etanercept and Minocycline in a rat model of spinal cord injury.</gtr:title><gtr:parentPublicationTitle>European journal of pain (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66ab55f34b2e253a9cada999918a79b0"><gtr:id>66ab55f34b2e253a9cada999918a79b0</gtr:id><gtr:otherNames>Marchand F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1090-3801</gtr:issn><gtr:outcomeId>EEB2CF7F4C9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C540CF2A-2A62-465B-98D9-45BC26CA77B3</gtr:id><gtr:title>Transplanted neural progenitor cells survive and differentiate but achieve limited functional recovery in the lesioned adult rat spinal cord.</gtr:title><gtr:parentPublicationTitle>Regenerative medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db28e2805c5490d0162abb23ac230c89"><gtr:id>db28e2805c5490d0162abb23ac230c89</gtr:id><gtr:otherNames>Webber DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1746-0751</gtr:issn><gtr:outcomeId>ACECF99A496</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9366160D-9026-4F87-BC25-DEF14791B9A4</gtr:id><gtr:title>Therapeutic time window for the application of chondroitinase ABC after spinal cord injury.</gtr:title><gtr:parentPublicationTitle>Experimental neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d3f066faae75e37a2caa4255313f4bc"><gtr:id>3d3f066faae75e37a2caa4255313f4bc</gtr:id><gtr:otherNames>Garc?a-Al?as G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0014-4886</gtr:issn><gtr:outcomeId>2123B5EF71D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5206939F-2D39-444C-9B8A-2A4B4FD32D3A</gtr:id><gtr:title>Chondroitinase ABC-mediated plasticity of spinal sensory function.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c43afb69f5a64f49d067d28c5eac467"><gtr:id>0c43afb69f5a64f49d067d28c5eac467</gtr:id><gtr:otherNames>Cafferty WB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>4BE61129B44</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D8FA3E7E-3299-4BA2-81C1-15673FE0B4CD</gtr:id><gtr:title>Spinal cord repair strategies: why do they work?</gtr:title><gtr:parentPublicationTitle>Nature reviews. Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c88446f52c6185f8535f769e99cafddd"><gtr:id>c88446f52c6185f8535f769e99cafddd</gtr:id><gtr:otherNames>Bradbury EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1471-003X</gtr:issn><gtr:outcomeId>3479128BD43</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>339C8667-09EE-4998-9BEE-0E8A67DAD5F4</gtr:id><gtr:title>Control of axonal growth and regeneration of sensory neurons by the p110delta PI 3-kinase.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3cb6ca371d4bd1b2dc06c1caac1ed52"><gtr:id>a3cb6ca371d4bd1b2dc06c1caac1ed52</gtr:id><gtr:otherNames>Eickholt BJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>A5986ADFA37</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F3A3B644-21E6-4611-B1A4-1AE349A209ED</gtr:id><gtr:title>Delayed treatment with chondroitinase ABC reverses chronic atrophy of rubrospinal neurons following spinal cord injury.</gtr:title><gtr:parentPublicationTitle>Experimental neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0684ff0a808a8056441bb17890a5be0d"><gtr:id>0684ff0a808a8056441bb17890a5be0d</gtr:id><gtr:otherNames>Carter LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0014-4886</gtr:issn><gtr:outcomeId>FG2o2qJhLPE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>23038DE2-08B0-40C1-AC36-69E1691CCF1F</gtr:id><gtr:title>Expression of the regeneration-associated protein SPRR1A in primary sensory neurons and spinal cord of the adult mouse following peripheral and central injury.</gtr:title><gtr:parentPublicationTitle>The Journal of comparative neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8a03d392a595ce88516148d840751941"><gtr:id>8a03d392a595ce88516148d840751941</gtr:id><gtr:otherNames>Starkey ML</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9967</gtr:issn><gtr:outcomeId>CDBF40EBC60</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8BD71C68-1119-40BA-967E-8DBB817D4510</gtr:id><gtr:title>A clonal cell line from immortalized olfactory ensheathing glia promotes functional recovery in the injured spinal cord.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fff504e93626a5b28f910cdd331f43bf"><gtr:id>fff504e93626a5b28f910cdd331f43bf</gtr:id><gtr:otherNames>Moreno-Flores MT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>F204238B0D7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D89408F4-2828-4E32-B781-A4C9E0D8A426</gtr:id><gtr:title>Lentiviral vector expressing retinoic acid receptor beta2 promotes recovery of function after corticospinal tract injury in the adult rat spinal cord.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/24d2482476a798cc557af102b034ebc7"><gtr:id>24d2482476a798cc557af102b034ebc7</gtr:id><gtr:otherNames>Yip PK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>411823FC02B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2B0AD1F-7323-4201-9FA7-A4AE014CBE91</gtr:id><gtr:title>Chondroitinase ABC promotes sprouting of intact and injured spinal systems after spinal cord injury.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a06f1f513cd8750a999d283e7d6a00a0"><gtr:id>a06f1f513cd8750a999d283e7d6a00a0</gtr:id><gtr:otherNames>Barritt AW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>ECCB67A66F3</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G120/818</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>